Skip to main content
. 2018 Apr 10;21(Suppl Suppl 2):e25052. doi: 10.1002/jia2.25052

Figure 2.

Figure 2

Reported restrictions on access to direct‐acting antivirals for the treatment of hepatitis C in study countries (N=25)